Patent · US Active

Cleavable radioligands for targeting cell surface receptors and uses thereof

US12214059B2 · kind B2 · utility

0Cited by
5References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 13, 2024
Grant dateFeb 4, 2025
Priority date—
Expiry dateMar 13, 2044

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K51/081
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present application relates to a compound or a pharmaceutically acceptable salt and/or solvate thereof comprising one or more circulation enhancing groups, one or more target binding groups, one or more chelating groups, at one least cleavable linker and at least one branching group that is at least trivalent. The application further includes a radionuclide complex or a pharmaceutically acceptable salt and/or solvate thereof, comprising a compound of the application or a pharmaceutically acceptable salt and/or solvate thereof, and one or more radionuclides, and to compositions comprising the compound or the complexes. The present application also includes methods of using the compounds, complexes and compositions for targeting and/or killing target cells. For example, the compound includes a compound of Formula I

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.